This review explores the pharmacology, mechanisms of action, and expanding clinical indications for 5-alpha reductase inhibitors (5-ARIs).
While traditionally used for benign prostatic hyperplasia (BPH), 5-ARIs have shown relevance in other clinical contexts. The review addresses the debunked link between finasteride and high-grade prostate cancer and details the adverse effects, including post-finasteride syndrome.
It also examines the potential role of 5-ARIs in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) due to their impact on the androgen axis. Although some claims remain unsubstantiated, the growing understanding of 5-ARIs suggests broader future applications.
